These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1421 related articles for article (PubMed ID: 19581794)

  • 21. Recurrences after conformal parotid-sparing radiotherapy for head and neck cancer.
    Bussels B; Maes A; Hermans R; Nuyts S; Weltens C; Van den Bogaert W
    Radiother Oncol; 2004 Aug; 72(2):119-27. PubMed ID: 15297131
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Treatment of nasopharyngeal carcinoma with intensity-modulated radiotherapy: the Hong Kong experience.
    Kam MK; Teo PM; Chau RM; Cheung KY; Choi PH; Kwan WH; Leung SF; Zee B; Chan AT
    Int J Radiat Oncol Biol Phys; 2004 Dec; 60(5):1440-50. PubMed ID: 15590175
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Intensity-modulated radiation therapy for oropharyngeal carcinoma: impact of tumor volume.
    Chao KS; Ozyigit G; Blanco AI; Thorstad WL; Deasy JO; Haughey BH; Spector GJ; Sessions DG
    Int J Radiat Oncol Biol Phys; 2004 May; 59(1):43-50. PubMed ID: 15093897
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Intensity-modulated radiotherapy with concurrent chemotherapy for previously irradiated, recurrent head and neck cancer.
    Biagioli MC; Harvey M; Roman E; Raez LE; Wolfson AH; Mutyala S; Han HS; Markoe A
    Int J Radiat Oncol Biol Phys; 2007 Nov; 69(4):1067-73. PubMed ID: 17967302
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Postoperative IMRT in head and neck cancer.
    Studer G; Furrer K; Davis BJ; Stoeckli SS; Zwahlen RA; Luetolf UM; Glanzmann C
    Radiat Oncol; 2006 Oct; 1():40. PubMed ID: 17052346
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Intensity-modulated radiation therapy without concurrent chemotherapy for stage IIb nasopharyngeal cancer.
    Tham IW; Lin S; Pan J; Han L; Lu JJ; Wee J
    Am J Clin Oncol; 2010 Jun; 33(3):294-9. PubMed ID: 20395788
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Radiation therapy in the management of head-and-neck cancer of unknown primary origin: how does the addition of concurrent chemotherapy affect the therapeutic ratio?
    Chen AM; Farwell DG; Lau DH; Li BQ; Luu Q; Donald PJ
    Int J Radiat Oncol Biol Phys; 2011 Oct; 81(2):346-52. PubMed ID: 20933340
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Multiagent concurrent chemoradiotherapy for locoregionally advanced squamous cell head and neck cancer: mature results from a single institution.
    Adelstein DJ; Saxton JP; Rybicki LA; Esclamado RM; Wood BG; Strome M; Lavertu P; Lorenz RR; Carroll MA
    J Clin Oncol; 2006 Mar; 24(7):1064-71. PubMed ID: 16505425
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Preservation of oral health-related quality of life and salivary flow rates after inverse-planned intensity- modulated radiotherapy (IMRT) for head-and-neck cancer.
    Parliament MB; Scrimger RA; Anderson SG; Kurien EC; Thompson HK; Field GC; Hanson J
    Int J Radiat Oncol Biol Phys; 2004 Mar; 58(3):663-73. PubMed ID: 14967418
    [TBL] [Abstract][Full Text] [Related]  

  • 30. IMRT using simultaneously integrated boost (SIB) in head and neck cancer patients.
    Studer G; Huguenin PU; Davis JB; Kunz G; Lütolf UM; Glanzmann C
    Radiat Oncol; 2006 Mar; 1():7. PubMed ID: 16722599
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Osteoradionecrosis of the mandible: minimized risk profile following intensity-modulated radiation therapy (IMRT).
    Studer G; Studer SP; Zwahlen RA; Huguenin P; Grätz KW; Lütolf UM; Glanzmann C
    Strahlenther Onkol; 2006 May; 182(5):283-8. PubMed ID: 16673062
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Marginal misses after postoperative intensity-modulated radiotherapy for head and neck cancer.
    Chen AM; Farwell DG; Luu Q; Chen LM; Vijayakumar S; Purdy JA
    Int J Radiat Oncol Biol Phys; 2011 Aug; 80(5):1423-9. PubMed ID: 20656416
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Comparison of hyperfractionation and conventional fractionation radiotherapy with concurrent docetaxel, cisplatin and 5-fluorouracil (TPF) chemotherapy in patients with locally advanced squamous cell carcinoma of the head and neck (SCCHN).
    Katori H; Tsukuda M; Watai K
    Cancer Chemother Pharmacol; 2007 Aug; 60(3):399-406. PubMed ID: 17096160
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Split course hyperfractionated accelerated radio-chemotherapy (SCHARC) for patients with advanced head and neck cancer: influence of protocol deviations and hemoglobin on overall survival, a retrospective analysis.
    Stadler P; Putnik K; Kreimeyer T; Sprague LD; Koelbl O; Schäfer C
    BMC Cancer; 2006 Dec; 6():279. PubMed ID: 17150114
    [TBL] [Abstract][Full Text] [Related]  

  • 35. IMRT reirradiation of head and neck cancer-disease control and morbidity outcomes.
    Sulman EP; Schwartz DL; Le TT; Ang KK; Morrison WH; Rosenthal DI; Ahamad A; Kies M; Glisson B; Weber R; Garden AS
    Int J Radiat Oncol Biol Phys; 2009 Feb; 73(2):399-409. PubMed ID: 18556144
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Is planned neck dissection necessary for head and neck cancer after intensity-modulated radiotherapy?
    Yao M; Hoffman HT; Chang K; Funk GF; Smith RB; Tan H; Clamon GH; Dornfeld K; Buatti JM
    Int J Radiat Oncol Biol Phys; 2007 Jul; 68(3):707-13. PubMed ID: 17379453
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Regional relapse after intensity-modulated radiotherapy for head-and-neck cancer.
    Duprez F; Bonte K; De Neve W; Boterberg T; De Gersem W; Madani I
    Int J Radiat Oncol Biol Phys; 2011 Feb; 79(2):450-8. PubMed ID: 20381266
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Evidence-based radiation oncology in head and neck squamous cell carcinoma.
    Corvò R
    Radiother Oncol; 2007 Oct; 85(1):156-70. PubMed ID: 17482300
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Analysis of radiation therapy for the control of Merkel cell carcinoma of the head and neck based on 36 cases and a literature review.
    Lawenda BD; Arnold MG; Tokarz VA; Silverstein JR; Busse PM; McIntyre JF; Deschler DG; Baldini EH; Kachnic LA
    Ear Nose Throat J; 2008 Nov; 87(11):634-43. PubMed ID: 19006065
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Risk factors for severe Dysphagia after concurrent chemoradiotherapy for head and neck cancers.
    Koiwai K; Shikama N; Sasaki S; Shinoda A; Kadoya M
    Jpn J Clin Oncol; 2009 Jul; 39(7):413-7. PubMed ID: 19383615
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 72.